(一)审议通过了《关于公司 <2023 年半年度报告>及其摘要的议案》 证券代码：301212 证券简称：联盛化学 公告编号：2023-031 浙江联盛化学股份有限公司 第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江联盛化学股份有限公司（以下简称"公司"）第三届监事会第九次会议（以 下简称"本次会议"）于 2023 年 8 月 28 日在公司会议室以现场结合通讯的方式召开。 会议通知于 2023 年 8 月 18 日通过邮件、传真或专人送达等方式发出。本次会议应出 席监事 3 名，实际出席监事 3 名，本次会议由监事会主席黄卫国先生主持。本次会议 的召集、召开及表决程序符合《中华人民共和国公司法》《中华人民共和国证券法》 等有关法律、行政法规、规范性文件、部门规章及《浙江联盛化学股份有限公司章 程》的相关规定，会议决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： 经审议，公司监事会认为公司 2023 年半年度报告的编制和审议程序符合相关法 律法规及《公司章程》等内部规章制 ...

证券代码：301212 证券简称：联盛化学 公告编号：2023-033 特别提示： 1、拟聘任会计师事务所名称：容诚会计师事务所（特殊普通合伙）（以下 简称"容诚会计师事务所"）； 2、原聘任会计师事务所名称：天健会计师事务所（特殊普通合伙）（以下 简称"天健会计师事务所"）； 浙江联盛化学股份有限公司 关于变更会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 3、变更会计师事务所的原因：鉴于天健会计师事务所已连续多年为浙江联 盛化学股份有限公司（以下简称"公司"）提供审计服务，为更好保证审计工作 的独立性，通过轮换审计机构强化公司治理，公司拟聘请容诚会计师事务所为公 司 2023 年度审计机构。公司已就变更会计师事务所的相关事宜与天健会计师事 务所进行了事先的沟通，天健会计师事务所明确知悉本事项，并已按照相关规定 与公司拟聘请的容诚会计师事务所做好了沟通，前后任会计师事务所对本次变更 事宜均无异议。 4、公司审计委员会、独立董事、董事会、监事会对本次变更会计师事务所 事项无异议。 公司于 2023 年 8 月 28 日召开了第三届董事会第十 ...

国金证券股份有限公司 关于浙江联盛化学股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：国金证券股份有限公司 | 被保荐公司简称：联盛化学 | | --- | --- | | 保荐代表人姓名：聂敏 | 联系电话：010-85142899 | | 保荐代表人姓名：张锋 | 联系电话：010-85142899 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2．督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | ...

因此，我们对聘请容诚会计师事务所（特殊普通合伙）为公司 2023 年度审 计机构的事项表示认可，并同意将该议案提交第三届董事会第十次会议审议。 （以下无正文，下接签署页） 【本页无正文，为《浙江联盛化学股份有限公司独立董事对第三届董事会第十 次会议相关事项的事前认可意见》之签署页】 浙江联盛化学股份有限公司 独立董事关于第三届董事会第十次会议 相关事项的事前认可意见 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》《上市公司独 立董事规则》《浙江联盛化学股份有限公司章程》以及《浙江联盛化学股份有限 公司独立董事工作细则》等有关法律、法规和规范性文件的规定，我们作为浙江 联盛化学股份有限公司（以下简称"公司"）的独立董事，在审阅有关文件后，基 于独立判断的立场，本着认真、严谨、负责的态度，秉承实事求是的原则，对拟 提交第三届董事会第十次会议审议的相关事项进行了认真审核，并发表如下事前 认可意见： 一、关于变更会计师事务所的事前认可意见 经核查，我们认为： ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江联盛化学股份有限公司（以下简称"公司"）第三届董事会第十次会议（以下 简称"本次会议"）于 2023 年 8 月 28 日在公司会议室以现场结合通讯的方式召开。会 议通知于 2023 年 8 月 18 日通过专人送出、邮件或传真等方式发出，会议应出席董事 8 人，实际出席董事 8 人。本次会议由公司董事长牟建宇女士召集和主持，公司监事、 高级管理人员列席了会议。本次会议的召集、召开及表决程序符合《中华人民共和国 公司法》《中华人民共和国证券法》等有关法律、行政法规、规范性文件、部门规章 及《浙江联盛化学股份有限公司章程》的相关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 证券代码：301212 证券简称：联盛化学 公告编号：2023-030 浙江联盛化学股份有限公司 第三届董事会第十次会议决议公告 （一）审议通过了《关于公司 <2023 年半年度报告>及其摘要的议案》 董事会认为公司 2023 年半年度报告及其摘要的编制符合相关法律法规及《公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥233,350,600.29, representing a 6.25% increase compared to ¥219,622,410.85 in the same period last year[4] - Net profit attributable to shareholders was ¥33,794,308.43, an increase of 85.09% from ¥18,258,381.70 year-on-year[4] - Basic earnings per share rose to ¥0.31, up 34.78% from ¥0.23 in the same period last year[4] - Net profit for Q1 2023 reached ¥33,805,783.03, up 68.5% from ¥20,060,843.88 in the same period last year[19] - Operating profit increased to ¥38,443,089.91, a rise of 63.3% compared to ¥23,547,646.61 in Q1 2022[19] - Total comprehensive income for Q1 2023 was ¥33,805,783.03, compared to ¥20,060,843.88 in the previous year, marking a 68.5% increase[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.31, up from ¥0.23 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥43,097,793.56, a significant increase of 844.55% compared to a negative cash flow of -¥5,788,404.68 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥43,097,793.56, a significant improvement from a negative cash flow of ¥5,788,404.68 in Q1 2022[21] - The net increase in cash and cash equivalents was ¥22,466,667.14, a 279.40% increase compared to a decrease of -¥12,523,509.37 in the previous year[9] - Cash and cash equivalents at the end of Q1 2023 totaled ¥273,129,358.57, an increase from ¥127,772,327.87 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,654,149,532.15, a slight increase of 0.32% from ¥1,648,907,339.15 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to CNY 1,654,149,532.15, a slight increase from CNY 1,648,907,339.15 at the beginning of the year[14] - Total liabilities decreased from CNY 303,585,791.80 to CNY 273,736,446.48, indicating a reduction of about 9.8%[16] - The company's total equity increased from CNY 1,345,321,547.35 to CNY 1,380,413,085.67, representing a growth of approximately 2.6%[16] Research and Development - Research and development expenses increased by 36.53% to ¥7,999,391.16, aimed at enhancing product competitiveness[8] - Research and development expenses rose to ¥7,999,391.16, up 36.5% from ¥5,859,191.13 year-over-year[18] - The company is actively engaged in research and development of new products and technologies, although specific details were not disclosed in the report[12] Shareholder Information - The number of common shareholders at the end of the reporting period was 9,691, with the largest shareholder holding 52.78% of the shares[11] - The company has a total of 57,000,000 shares held by the largest shareholder, 联盛化学集团, which represents a significant portion of the ownership structure[11] Inventory and Receivables - Inventory levels decreased from CNY 107,264,309.16 to CNY 77,704,492.65, a decline of about 27.5%[15] - Accounts receivable rose from CNY 130,926,297.97 to CNY 159,672,876.01, an increase of approximately 21.9%[14] Financial Expenses and Taxation - The company reported a significant decrease in financial expenses, with a net income of -¥2,476,599.69, compared to ¥1,865,161.69 in the same period last year, due to increased interest income from raised funds[8] - The company experienced a 152.07% increase in taxes and surcharges, amounting to ¥1,131,233.33, attributed to higher revenue[8] Operating Costs - Total operating costs decreased to ¥194,039,600.39 from ¥194,983,743.05, reflecting a reduction of 0.5%[18]

证券代码：301212 证券简称：联盛化学 公告编号：2023-018 浙江联盛化学股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 浙江联盛化学股份有限公司（以下简称"公司"）已于 2023 年 04 月 19 日在 深圳证券交易所网站（www.szse.cn）及巨潮资讯网(www.cninfo.com.cn)上披露了 《浙江联盛化学股份有限公司 2022 年年度报告》及《浙江联盛化学股份有限公 司 2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业 绩、发展战略等情况，公司定于 2023 年 05 月 05 日（星期五）15:00-16:00 在"价 值在线"（www.ir-online.cn）举办浙江联盛化学股份有限公司 2022 年度业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 会议召开时间：2023 年 05 月 05 日（星期五）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） ...

Financial Performance - The company's operating revenue for 2022 was ¥1,041,133,695.75, representing a 24.98% increase compared to ¥833,013,848.92 in 2021[18] - The net profit attributable to shareholders for 2022 was ¥182,965,402.93, a significant increase of 106.69% from ¥88,520,742.84 in the previous year[18] - The basic earnings per share for 2022 rose to ¥1.85, up 69.72% from ¥1.09 in 2021[18] - The total assets at the end of 2022 reached ¥1,648,907,339.15, an 88.08% increase from ¥876,682,063.24 at the end of 2021[18] - The net assets attributable to shareholders increased by 208.58% to ¥1,313,229,934.85 from ¥425,575,774.53 in 2021[18] - The weighted average return on equity for 2022 was 18.47%, down from 23.17% in 2021, indicating a decrease in profitability[18] - The company achieved a total operating revenue of CNY 1,041,133,695.75, representing a year-on-year growth of 24.98%[72] - The total profit reached CNY 21,874.38 million, an increase of 106.76% compared to the previous year[64] - The net profit attributable to shareholders was CNY 18,296.54 million, reflecting a growth of 106.69% year-on-year[64] Cash Flow and Investments - The net cash flow from operating activities for 2022 was negative at -¥5,026,134.96, a decline of 102.78% compared to ¥180,777,134.66 in 2021[18] - Operating cash inflow totaled CNY 1,025,322,525.02, an increase of 25.81% compared to CNY 814,981,650.79 in 2021[87] - Net cash flow from operating activities decreased by 102.78%, resulting in a net outflow of CNY 5,026,134.96, primarily due to increased use of bank acceptance bills for sales payments[87] - Investment cash inflow dropped by 91.11% to CNY 4,427,779.39, while investment cash outflow surged by 627.10% to CNY 561,907,065.78, leading to a net cash outflow of CNY 557,479,286.39, a decrease of 1,928.55%[87] - Financing cash inflow increased significantly by 1,718.86% to CNY 848,048,962.26, mainly due to funds raised from a public stock issuance[87] Research and Development - The company invested CNY 25.56% more in R&D, with 5 new patents granted, totaling 34 authorized patents by the end of 2022[65] - Research and development expenses rose by 25.56% to ¥32,940,383.29 in 2022, compared to ¥26,235,612.57 in 2021[81] - R&D investment amounted to ¥32,940,383.29 in 2022, representing a 25.5% increase from ¥26,235,612.57 in 2021[86] - The number of R&D personnel increased to 48 in 2022, a 9.09% rise from 44 in 2021[86] - The company aims to enhance product competitiveness through technology upgrades and optimization of existing production processes[85] Market and Industry Trends - The fine chemical industry in China is projected to grow from a market size of approximately CNY 5.5 trillion in 2021 to CNY 11 trillion by 2027, with a compound annual growth rate (CAGR) of 8% from 2016 to 2021[30] - The revenue of the chemical raw materials and products manufacturing industry increased from CNY 6.5 trillion in 2017 to CNY 9.1 trillion in 2022, with a CAGR of 11.50% from 2017 to 2022[32] - The pharmaceutical intermediate market in China is expected to exceed RMB 290 billion by 2026, driven by both domestic and global pharmaceutical market growth[38] - The global pesticide industry is experiencing an upward trend, with major multinational companies holding over 60% market share, indicating a favorable environment for leading raw material enterprises[39] - China's electronic chemicals market is projected to reach RMB 448 billion by 2026, with a compound annual growth rate of 6.45%[41] Risk Management - The company faces risks including macroeconomic fluctuations, raw material price volatility, and production safety risks, which may impact future performance[4] - The company emphasizes the importance of risk awareness for investors regarding future plans and strategies[4] - The company is actively addressing risks related to raw material price fluctuations by monitoring price trends and optimizing procurement strategies[133] - The company has implemented risk control measures for its financial derivative trading, focusing on hedging against exchange rate and interest rate risks[104] Corporate Governance - The company has established a complete and independent procurement, research and development, production, and sales system, ensuring operational independence from its controlling shareholder[155] - The company has a fully independent labor and personnel management system, with all senior management personnel exclusively working for the company and not holding positions in the controlling shareholder's enterprises[157] - The company has updated and revised 21 governance documents to enhance its governance structure, ensuring compliance with relevant laws and regulations[147] - The company emphasizes investor relations management, providing multiple communication channels for investors and actively responding to their concerns[154] - The company has established a strategic committee, audit committee, nomination committee, and compensation and assessment committee to support the board's decision-making process[150] Employee and Talent Management - The company has a total of 411 employees, with 274 in production, 48 in technical roles, and 67 in administration[190] - The company has established a competitive compensation system to attract and retain talent, including a long-term equity incentive plan for key management and technical personnel[191] - The company has a comprehensive training system in place, offering various training programs to enhance employee skills and professional development[192] - The company has a structured remuneration decision process based on performance evaluations and company operating results[177] Dividend Distribution - The company plans to distribute a cash dividend of ¥3.80 per 10 shares (including tax) based on a base of 108,000,000 shares[4] - The total distributable profit for the year was 339,860,116.31 CNY, with the cash dividend representing 100% of the profit distribution[195] - The company did not issue any bonus shares or increase capital from reserves during this distribution[197] - The company is in a growth phase and aims for a minimum cash dividend ratio of 20% in profit distribution[196] Production and Operations - The company has developed advanced technologies such as dehydrogenation-hydrogenation cycle technology and continuous production technology, facilitating its transition from manufacturing to intelligent manufacturing[45] - The production capacity utilization rates for key products are as follows: GBL at 57.99%, ABL at 67.29%, CPMK at 19.88%, IPA at 59.81%, E2 at 15.07%, PEO at 60.39%, and HDO at 4.53%[52] - The company has established long-term stable partnerships with renowned pharmaceutical companies, enhancing its market credibility and brand advantage[47] - The company has implemented continuous production for key products such as GBL, ABL, IPA, HDO, and PEO, with ABL production recognized as a "2022 Zhejiang Province First Batch Digital Workshop"[58]

Revenue and Profit - Revenue for Q3 2022 reached ¥252,459,768.99, an increase of 66.06% year-over-year[4] - Net profit attributable to shareholders was ¥58,684,970.20, a significant increase of 420.25% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥60,482,619.71, up 504.64% year-over-year[4] - Basic earnings per share for Q3 2022 was ¥0.54, reflecting a 285.71% increase from the previous year[4] - Revenue for the first nine months of 2022 reached CNY 774.80 million, a 31.55% increase compared to CNY 588.99 million in the same period of 2021[8] - Net profit for the first nine months of 2022 was CNY 146.99 million, representing a 97.09% increase from CNY 74.58 million in the same period of 2021[8] - The total profit for the first nine months of 2022 was CNY 171.32 million, a 102.11% increase compared to CNY 84.76 million in the same period of 2021[8] - The total profit for Q3 2022 was CNY 171,319,787.39, compared to CNY 84,764,259.86 in Q3 2021, representing a year-over-year increase of 102.3%[17] - The net profit attributable to shareholders of the parent company reached CNY 142,515,984.86, up from CNY 70,322,076.90 in the same period last year, marking a growth of 102.4%[17] Assets and Equity - Total assets as of September 30, 2022, amounted to ¥1,681,078,746.85, representing a 91.75% increase from the end of the previous year[4] - Shareholders' equity attributable to the company reached ¥1,272,832,360.98, a 199.08% increase compared to the previous year-end[4] - The company’s total assets increased by 426.92% in other non-current assets, reaching CNY 38.21 million, due to increased prepayments for projects and equipment[8] - Total assets as of September 30, 2022, were CNY 1,681,078,746.85, compared to CNY 876,682,063.24 at the beginning of the year, reflecting a growth of 91.5%[14] - Current assets totaled CNY 1,243,250,100.81, significantly up from CNY 472,459,926.95 at the start of the year, marking a 163.0% increase[13] - The company’s equity attributable to shareholders rose to CNY 1,272,832,360.98, up from CNY 425,575,774.53, an increase of 199.5%[15] Cash Flow and Financing - Cash flow from operating activities for the year-to-date was ¥15,863,771.42, showing a decline of 89.75%[4] - Cash and cash equivalents increased by 444.04% to ¥785,666,926.39, mainly due to funds raised from a public stock offering[7] - Cash flow from operating activities decreased by 89.75% to CNY 15.86 million, mainly due to an increase in accounts receivable[8] - Operating cash inflow totaled CNY 712,493,396.88, an increase from CNY 612,829,685.11 in the previous year, indicating a growth of 16.3%[19] - The net cash flow from operating activities was CNY 15,863,771.42, down from CNY 154,797,601.88 in the same quarter last year, showing a decline of 89.7%[19] - The company raised CNY 749,048,962.26 from investment activities, a significant increase compared to the previous year[19] - The net cash flow from financing activities was CNY 661,422,287.18, compared to a negative cash flow of CNY -53,689,501.44 in the same period last year[19] Costs and Expenses - Total operating costs amounted to CNY 602,229,041.28, up 19.4% from CNY 504,484,775.34 in the prior period[16] - Research and development expenses for the period were CNY 23,253,115.75, compared to CNY 20,533,558.99 in the previous period, indicating a 8.3% increase[16] Non-Recurring Items - The company reported a non-recurring loss of ¥1,797,649.51 for Q3 2022, primarily due to foreign exchange derivative investment losses[5] - The company reported a significant increase in investment income, rising 578.07% to CNY 1.68 million, attributed to gains from derivative financial instruments[8] Other Information - The company did not undergo an audit for the Q3 2022 report[20]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in the same period of 2021[13]. - The net profit attributable to shareholders for the first half of 2022 was RMB 150 million, up 20% from RMB 125 million in the first half of 2021[13]. - The company's operating revenue for the reporting period was ¥522,341,137.70, representing a year-on-year increase of 19.54% compared to ¥436,967,560.50[21]. - The net profit attributable to shareholders was ¥83,831,014.66, marking a significant increase of 41.99% from ¥59,041,824.64 in the same period last year[21]. - The total profit reached 100.12 million yuan, up 36.16% compared to the same period last year[47]. - The company reported a net cash flow from operating activities of -¥46,867,798.45, a decline of 250.38% compared to ¥31,165,551.17 in the previous year[21]. - The company’s basic and diluted earnings per share increased by 27.40% to ¥0.93 from ¥0.73 in the same period last year[21]. - The company has set a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth rate of 20%[13]. Investment and Development - The company plans to invest RMB 300 million in new product development and technology research in the upcoming year[13]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[13]. - The company plans to extend its BDO industrial chain towards ultra-pure electronic chemicals and biodegradable new materials, enhancing its position in the specialty fine chemical sector[29]. - The company is currently engaged in new projects, including ultra-pure electronic chemicals and biodegradable materials, with a total investment of ¥15.06 million in the reporting period[74]. - The company has filed for multiple patents, with two new patents related to α-acetyl-γ-butyrolactone and cosmetic-grade 1,2-hexanediol purification equipment[48]. - The company has 31 authorized patents, including 22 invention patents, showcasing its strong R&D capabilities[50]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by the end of 2023[13]. - User data indicates a 25% increase in customer base, growing from 10,000 to 12,500 active users[13]. - The company serves notable clients including Bayer Group and Syngenta, indicating strong market relationships and demand for its products[29]. - The company is focusing on expanding its customer base both domestically and internationally to reduce reliance on a limited number of clients[107]. Risk Management - The company faces risks related to raw material price fluctuations and macroeconomic volatility, which may impact future performance[4]. - The company is closely monitoring raw material prices, which include BDO, ethyl acetate, and others, to manage procurement costs effectively[102]. - The company has implemented risk control measures for its derivative investments to mitigate potential losses from currency fluctuations[94]. - The company is taking steps to hedge against foreign exchange risks due to its export-oriented business model, primarily denominated in USD[106]. Environmental and Safety Compliance - The company has implemented a comprehensive safety and environmental management system, enhancing its overall competitiveness[57]. - The company has obtained environmental impact assessments and pollutant discharge permits for all production projects, ensuring compliance with regulations[123]. - The company has established EHS departments and dedicated personnel to ensure compliance with environmental regulations and standards[120]. - The company has implemented an emergency response plan for environmental incidents, with regular drills and evaluations conducted[124]. - The wastewater treatment facility at Liansheng Chemical has a daily processing capacity of 300 tons, with no exceedances reported during the reporting period[120]. - The company emphasizes safety management, adhering to national safety production laws and regulations, with no major safety incidents reported during the reporting period[139]. Financial Position and Assets - The company's total assets increased by 102.87% to ¥1,778,503,593.26 from ¥876,682,063.24 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 185.25% to ¥1,213,957,713.04 from ¥425,575,774.53 at the end of the previous year[21]. - The company's cash and cash equivalents as of June 30, 2022, amount to ¥843,309,215.07, a significant increase from ¥144,413,440.96 at the beginning of the year[194]. - The total current assets reached ¥1,354,206,278.69, up from ¥472,459,926.95, marking a substantial growth of approximately 187%[194]. - The company's equity increased significantly to CNY 1,240,581,889.59 from CNY 453,968,753.49, marking a growth of 173.5%[196]. Corporate Governance - The company held 4 board meetings, 2 shareholder meetings, and 4 supervisory meetings during the reporting period, reviewing a total of 83 proposals[130]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[128]. - The company has not experienced any significant changes in the feasibility of the investment projects[87]. - The company has not engaged in any entrusted loans during the reporting period[95]. - The company has not made any changes to the use of raised funds during the reporting period[89]. Shareholder Information - The company completed its initial public offering of 27 million shares, increasing the total share capital from 81 million to 108 million shares[172]. - The company’s shareholding structure includes 76.29% of limited shares and 23.71% of unrestricted shares after the recent issuance[171]. - The total number of ordinary shareholders at the end of the reporting period is 18,894, with the largest shareholder, Liansheng Chemical Group Co., Ltd., holding 52.78% of shares, equating to 57,000,000 shares[181].